NCT07350785 Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
| NCT ID | NCT07350785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National and Kapodistrian University of Athens |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-12-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hip fracture is a common injury in older adults and is often associated with serious complications, longer hospital stays, and increased risk of death. One of the most important causes of poor outcomes after hip fracture surgery is infection, including severe infections such as sepsis. Early identification of patients at higher risk for complications could help improve treatment and survival. This study aims to examine whether a blood test parameter called Monocyte Distribution Width (MDW), along with other commonly used inflammatory markers, can help predict complications and survival in elderly patients with hip fracture. MDW is measured as part of a routine complete blood count and has shown promise in the early detection of infection and systemic inflammation. Approximately 100 patients aged 65 years or older who are admitted to the hospital with a low-energy hip fracture will be included in this study. Blood tests will be performed at hospital admission, after surgery, and at other time points as part of standard clinical care. These tests include routine blood counts and inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), antithrombin III, and MDW. No additional invasive procedures are required beyond standard medical care. Researchers will collect information about each patient's medical history, overall health status, and daily activity level before the fracture. Patients will be followed after surgery to assess complications, length of hospital stay, and survival at 1 month, 3 months, and 1 year. The results of this study may help determine whether MDW can be used as a simple and reliable marker to identify patients at higher risk of complications or death after hip fracture. This could support earlier intervention, closer monitoring, and improved care for elderly patients with hip fractures in the future.
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥65 years * Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture) * Admission to General Hospital of Attica KAT * Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers Exclusion Criteria: * Age \<65 years * High-energy trauma-related hip fractures * Pathological fractures
Contact & Investigator
Efstathios Chronopoulos
STUDY DIRECTOR
KAT General Hospital, Athens Greece
Frequently Asked Questions
Who can join the NCT07350785 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07350785 currently recruiting?
Yes, NCT07350785 is actively recruiting participants. Contact the research team at stathi24@yahoo.gr for enrollment information.
Where is the NCT07350785 trial being conducted?
This trial is being conducted at Kifissia, Greece.
Who is sponsoring the NCT07350785 clinical trial?
NCT07350785 is sponsored by National and Kapodistrian University of Athens. The principal investigator is Efstathios Chronopoulos at KAT General Hospital, Athens Greece. The trial plans to enroll 100 participants.